Finance

Lists
Why is SGIOY up 4,10%?
Dive Deeper
SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
9,13 $
+4,10%
(+0,36) 1D
15 қаз., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGIOY...
Open
9,53 $
High
9,53 $
Low
8,95 $
Mkt. cap
2,61 трлн
Avg. vol.
172,76 м.
Volume
120,07 м.
52-wk high
12,00 $
52-wk low
7,83 $
Beta
0,07
Shares outstanding
1,78 млрд
No. of employees
6 мың
Open
9,53 $
High
9,53 $
Low
8,95 $
Mkt. cap
2,61 трлн
Avg. vol.
172,76 м.
Volume
120,07 м.
52-wk high
12,00 $
52-wk low
7,83 $
Beta
0,07
Shares outstanding
1,78 млрд
No. of employees
6 мың
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
14 сағат бұрын
Jefferies sets JPY 3,900.00 target for Shionogi stock
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi 2 ADR Representing 1 Ord Shs
CEOIsao Teshirogi
Employees6,22 мың
Founded1878
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
113,18 млрд
147,72 млрд
138,99 млрд
163,31 млрд
Cost of goods sold
16,94 млрд
25,09 млрд
28,10 млрд
30,80 млрд
Cost of revenue
16,94 млрд
25,09 млрд
28,10 млрд
30,80 млрд
Research and development expenses
27,55 млрд
29,87 млрд
40,54 млрд
31,79 млрд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,56 млрд
35,27 млрд
32,92 млрд
44,36 млрд
Operating expense
56,57 млрд
48,45 млрд
100,06 млрд
113,87 млрд
Total operating expenses
73,51 млрд
73,54 млрд
128,17 млрд
144,66 млрд
Operating income
39,67 млрд
74,18 млрд
10,83 млрд
18,64 млрд
Other non operating income
-
-1,00 млн
7,31 млрд
-2,00 млн
EBT including unusual items
52,06 млрд
92,89 млрд
47,64 млрд
73,74 млрд
EBT excluding unusual items
52,06 млрд
93,10 млрд
47,80 млрд
25,47 млрд
Income tax expense
7,87 млрд
18,21 млрд
-56,00 млн
-23,98 млрд
Effective tax rate
15,12%
19,60%
-0,12%
-32,52%
Other operating expenses
979,00 млн
-17,25 млрд
15,44 млрд
21,90 млрд
Net income
44,19 млрд
74,68 млрд
46,93 млрд
97,70 млрд
Net profit margin
39,04%
50,56%
33,77%
59,82%
Earnings per share
-
-
-
-
Interest and investment income
14,21 млрд
20,53 млрд
23,73 млрд
12,15 млрд
Interest expense
-1,82 млрд
-1,61 млрд
-
-5,32 млрд
Net interest expenses
12,38 млрд
18,92 млрд
23,73 млрд
6,82 млрд
Depreciation and amortization charges
-485,00 млн
-
-1,53 млрд
-
EBITDA
44,83 млрд
80,21 млрд
21,59 млрд
39,52 млрд
Gain or loss from assets sale
-
-
35,04 млрд
-
AI content may include mistakes. Learn more
Google қолданбалары